Home › Trials › NCT05772559
Clinical trial Recruiting at 28 sites Observational Ages Any age to 25

Molecular profiling and drug testing for pediatric acute myeloid leukemia

Official title: Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies - ALARM3

Run by Assistance Publique - Hôpitaux de Paris · NCT05772559 · Data updated 2026-11-12

This study is trying to learn more about pediatric acute myeloid leukemia by looking at patients' cells to find out why some treatments don’t work and to test new drug options for kids and young adults with this cancer.

Quick facts

Study typeObservational
AgesAny age to 25 Years
SexAll
Enrollment500 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations28 sites (Amiens and 27 other locations)
StatusRecruiting
StartedMay 31, 2023
Main results expectedMay 31, 2033
Study endsMay 31, 2033
Registry record updatedJune 26, 2024
Trial IDNCT05772559 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals aged 0-25 years with newly diagnosed or relapsed acute myeloid leukemia, or those with a genetic predisposition to the disease.

Probably not a fit

Patients with chronic myeloid leukemia or those who refuse to participate may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on understanding pediatric acute myeloid leukemia (AML) by collecting biological samples from patients at initial diagnosis and during relapse. It aims to evaluate the genomic profiling of leukemic cells to identify genetic factors associated with treatment resistance and relapse risk. Additionally, the study will investigate the interaction of bone marrow mesenchymal stem cells and conduct ex vivo drug testing to explore potential therapeutic options. The research is observational and involves patients aged 0-25 years with various forms of AML.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies and better outcomes for children and young adults with acute myeloid leukemia.

How similar studies have gone: While this approach is focused on pediatric AML, similar studies in adult populations have shown promise in understanding genetic factors and improving treatment outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 0-25 years old
* Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or
* Relapsed or refractory AML or
* Patients with genetic predisposition to develop AML or
* Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care
* Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over.

Exclusion Criteria:

* Refuse to participate
* Chronic myeloid leukemia (CML)
* Lack of health insurance (French social security)
* Under protection (tutelle, curatelle or sauvegarde de justice)
* Pregnancy or breastfeeding

Where it's running

  • CHU Amiens Picardie site Sud
    Amiens, France     Recruiting
  • CHU Angers
    Angers, France     Recruiting
  • Hopital Minjoz
    Besançon, France     Recruiting
  • CHU Pellegrin
    Bordeaux, France     Recruiting
  • CHRU Morvan
    Brest, France     Recruiting
  • CHU Caen
    Caen, France     Recruiting
Show 22 more locations
  • CHU Estaing
    Clermont-Ferrand, France     Recruiting
  • CHU Francois Mitterand
    Dijon, France     Recruiting
  • CHU Grenoble
    Grenoble, France     Recruiting
  • CHU de la Réunion
    La Réunion, France     Recruiting
  • Hopital Jeanne de Flandre - CHRU
    Lille, France     Recruiting
  • CHU Limoges
    Limoges, France     Recruiting
  • HCL Lyon
    Lyon, France     Recruiting
  • Hôpital d'Enfants de la Timone
    Marseille, France     Recruiting
  • CHU Montpellier
    Montpellier, France     Recruiting
  • CHRU Nancy- Hopitaux de Brabois
    Nancy, France     Recruiting
  • CHU Nantes
    Nantes, France     Recruiting
  • CHU Nice
    Nice, France     Recruiting
  • Hopital Robert Debré
    Paris, France     Recruiting
  • Hopital Trousseau
    Paris, France     Recruiting
  • CHU Poitiers
    Poitiers, France     Recruiting
  • Hopital Américain
    Reims, France     Recruiting
  • CHU Hopital Sud
    Rennes, France     Recruiting
  • CHU Rouen
    Rouen, France     Recruiting
  • CHU Saint Etienne
    Saint-Etienne, France     Recruiting
  • Hopital Hautepierre
    Strasbourg, France     Recruiting
  • CHU Toulouse
    Toulouse, France     Recruiting
  • CHRU Tours
    Tours, France     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Acute Myeloid Leukemia 453Genetic Predisposition to Disease 17Assistance Publique - Hôpitaux de Paris 536
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.